Status:
RECRUITING
A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18+ years
Brief Summary
The main purpose of the study is to evaluate participant satisfaction after administration of ocrelizumab subcutaneous (SC) after 12 months using the therapy administration satisfaction questionnaire ...
Eligibility Criteria
Inclusion
- Diagnosis of MS
- RMS and PPMS participants diagnosed according to the McDonald criteria of 2017
- First treatment during the course of MS therapy with ocrelizumab SC according to the local prescribing information, regardless of the reason for starting treatment with ocrelizumab
Exclusion
- Participation in interventional studies investigating DMTs for MS
- Prior or simultaneous participation in CONFIDENCE or MoOzaRt (ISRCTN55332718) non interventional study (NIS) at the same study site
- Prior treatment with rituximab (MabThera®) or ublituximab (Briumvi®)
- Severe psychiatric disability
- Pregnant women
Key Trial Info
Start Date :
September 26 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 31 2028
Estimated Enrollment :
842 Patients enrolled
Trial Details
Trial ID
NCT06780150
Start Date
September 26 2024
End Date
March 31 2028
Last Update
March 2 2026
Active Locations (74)
Enter a location and click search to find clinical trials sorted by distance.
1
Uniklinik RWTH Aachen
Aachen, Germany, 52074
2
Neuropraxis im Stadtpalais Dres. Ulzheimer/Herröder/Wessig GbR
Aschaffenburg, Germany, 63739
3
Neurologie Bad Soden
Bad Soden, Germany, 65812
4
Neurologische Praxis - Kallmann Neurologie - mszb
Bamberg, Germany, 96052